Current prevalence and patterns of hypolipidemic medication based on real-life nation-wide data on 10, 816, 286 individuals

Konstantinos Mathioudakis; Maria Yavropoulou; Koloutsou Maria Evangelia; Polyzois Makras; Evangelos Liberopoulos; Konstantinos Athanasakis

doi:10.1530/endoabs.99.P298

P298

Prev Next

Section Contents Cite

Endocrine Abstracts (2024) 99 P298 | DOI: 10.1530/endoabs.99.P298

ECE2024 Poster Presentations Diabetes, Obesity, Metabolism and Nutrition (130 abstracts)

Current prevalence and patterns of hypolipidemic medication based on real-life nation-wide data on 10, 816, 286 individuals

Konstantinos Mathioudakis ¹ , Maria Yavropoulou ² , Maria Evangelia Koloutsou ² , Polyzois Makras ³ , Evangelos Liberopoulos ⁴ & Konstantinos Athanasakis ⁵

Views

Author affiliations

¹IDIKA SA - E-Government Center for Social Security Services, Athens, Greece; ²First Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece; ³Department of Medical Research, 251 Hellenic Air Force & VA General Hospital, 3 Kanellopoulou St, 11525, Athens, Greece; ⁴First Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece; ⁵Laboratory for Health Technology Assessment (LabHTA), Department of Public Health Policy, School of Public Health, University of West Attica, Athens, 11521, Greece

Background: Hypercholesterolemia has an established causal role in the progression of atherosclerosis and development of cardiovascular disease (CVD). In studies carried out after 2002, the estimated prevalence of self-reported dyslipidemia in the Greek population ranges from 11% to 23%, whereas approximately 35% of mortality in Greece is attributed to cardiovascular disease (CVD). Relevant real-life data, however, are scarce.

Methods: In the present study we used theelectronic prescription database of the National Organization for Health Care Services Provision (IDIKA), embracing almost 100% of all prescriptions issued in Greece, to capture individuals who received hypolipidemic treatment during the year 2021.

Results: The study population consisted of 10,482,487individuals, accounting for the totalGreek population in 2021. The overall prevalence of medication-prescribed dyslipidemia accounted for the 19% of the total Greek population (n=1,998,393), beingslightly higher in women than in men (19.7% vs 18%, respectively) across all age groups and was gradually increased with advancing age (7% in those < 50 years, to 44.5% in those aged 70 and above). Notably, 1052 individuals with medication-prescribed dyslipidemia were underage (accounting for 0.05% of the total underage population in Greece). Most common concomitant diseases were arterial hypertension (45.7%) diabetes type mellitus 2 (28.4 %), and coronary artery disease (14.4%). General practitioners(33,72%), Internists(33,69%), and Cardiologists(21,64%) prescribed the vast majority of hypolipidemic treatment. The annual cost of treatment per-patient was on average 144€ (total cost € 203,375,511)with rosuvastatin and atorvastatin being more frequently prescribed accounting for more than 80% of all prescriptions.

Conclusion: Approximately 18% of the total Greek population has been prescribed with a hypolipidemic agent during 2021. Prevention and control of dyslipidemia, as one of the most important modifiable risk factors for CVDremains a yet unmet challenge.

Keywords: dyslipidemia; hypolipidemic treatment; statins; cardiovascular disease; prevalence of dyslipidemia; Greek population